Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 10;8(4):20552173221132469.
doi: 10.1177/20552173221132469. eCollection 2022 Oct-Dec.

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate

Jennifer Lyons  1 , Richard Hughes  1 , Kerry McCarthy  1 , Nicholas Everage  1 , Shivani Kapadia  1 , Catherine Miller  1 , Priya Singhal  1 , Karen Smirnakis  1
Affiliations

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate

Jennifer Lyons et al. Mult Scler J Exp Transl Clin. .

Erratum in

Abstract

Background and objectives: Dimethyl fumarate (DMF), an oral disease-modifying therapy with an established benefit and well-described safety profile, is among the most commonly used therapies for relapsing forms of multiple sclerosis. As of 31 December 2021, >560,000 patients have been treated with DMF, representing >1,190,000 person-years of exposure. Of these, 6413 patients (14,292 person-years) were from clinical trials.

Methods and results: Progressive multifocal leukoencephalopathy (PML) has occurred in the setting of lymphopenia (<0.91 × 109/L) in patients treated with DMF. We present detailed clinical characteristics and outcomes of the 12 confirmed PML cases occurring in MS patients on DMF as of 21 July 2021. The PML incidence in DMF-treated patients is 1.07 per 100,000 person-years of DMF exposure. Lymphopenia is the common risk for PML in DMF treatment.

Discussion: DMF-related PML is rare but has occurred in the setting of lymphopenia, supporting the current recommendations for absolute lymphocyte count monitoring in all patients, regardless of age and time on therapy.

Keywords: John Cunnigham virus; Multiple sclerosis; dimethyl fumarate; immune suppression; progressive multifocal leukoencephalopathy; viral infections.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jennifer Lyons, Richard Hughes, Kerry McCarthy, Nicholas Everage, Catherine Miller, Priya Singhal and Karen Smirnakis are employees of and shareholders in Biogen. Shivani Kapadia is a former employee of Biogen.

Figures

Figure 1.
Figure 1.
Scores for (a) EDSS and (b) Karnofsky in individual patients with PML.
See this image and copyright information in PMC

References

    1. Jordan AL, Yang J, Fisher CJet al. et al. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler 2022; 28(1): 7–15. - PMC - PubMed
    1. Kartau M, Sipila JO, Auvinen Eet al. et al. Progressive multifocal leukoencephalopathy: current insights. Degener Neurol Neuromuscul Dis 2019; 9: 109–121. - PMC - PubMed
    1. Patel A, Sul J, Gordon ML, et al. Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol 2021; 78: 736–740. - PMC - PubMed
    1. Giovannoni GKL, Berger J, Cutter Get al. Updated incidence of natalizumab-associated progressive multifocal leukoencephalopathy (PML) and its relationship with natalizumab exposure over time. In: Paper presented at: American Academy of Neurology 2020–72nd Annual Meeting, 2020.
    1. Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 2018; 90: e1815–e1821. - PMC - PubMed